Sign in
Active, not recruitingNo phase

Post Market Clinical Follow-up of EUROSTEM Femoral Stem

Key facts

Who runs it
EUROS
Where
France9 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
131 people, planned
Started
21 May 2021
Expected to end
6 Nov 2032
Type of study
Observational
Treatments tested
  • hip arthroplasty
Record updated
20 February 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patient who received EUROSTEM
  • Patient informed of its participation to the study
  • Patient aged over 18 to date of surgery

Who cannot take part

  • Patient presenting a contraindication to EUROSTEM implantation
  • Patient who refused to participate to the study
  • Vulnerable subjects

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

EUROSSTEM is intended for use in primary and revision total hip replacement surgery.

Read full original descriptionShow less

Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components.

As part of post market vigilance, EUROS will collect data on EUROSTEM performances and safety

The group in the trial

  • EUROSTEM femoral stem

    All patients who received EUROSTEM femoral stem whatever the version (cemented or cementless)

    Treatment: hip arthroplasty

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
20 February 2024